Find a Clinical Trial

Filter

Showing 11 - 20 out of 26

A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients

Pulmonary hypertension

All genders

18+

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Tufts Medical Center

Learn more

A Phase 3 Study of Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality

Pulmonary hypertension

All genders

18-75

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Tufts Medical Center

Learn more

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 (S1918)

Diffuse large B-cell lymphoma

All genders

75+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

TETON-PPF

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

Pulmonary fibrosis

All genders

18-100

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Tufts Medical Center

Learn more

Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

Pulmonary fibrosis

All genders

40+

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Tufts Medical Center

Learn more

Keros PAH Study

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to
Investigate the Safety and Efficacy of KER-012 in Combination with
Background Therapy in Adult Participants with Pulmonary Arterial
Hypertension (TROPOS Study)

Pulmonary arterial hypertension (PAH)

All genders

18-100

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Tufts Medical Center

Learn more

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

A051902, A randomized phase II study of CHO(E)P vs CC-486- CHO(E)P vs duvelisib- CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas

Lymphomas (adult)

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-OLE)

An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

Pulmonary fibrosis

All genders

40-99

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Tufts Medical Center

Learn more

A Long-term Follow-up Study of Sotatercept for PAH Treatment

An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

Pulmonary hypertension

All genders

18+

Recruiting now

Department of Medicine, Division of Pulmonary, Critical Care + Sleep Medicine

Tufts Medical Center

Learn more

ANHL1931

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Lymphoma

All genders

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality

A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

A Randomized, Phase 2, Double-blind, Placebo-controlled Study to
Investigate the Safety and Efficacy of KER-012 in Combination with
Background Therapy in Adult Participants with Pulmonary Arterial
Hypertension (TROPOS Study)

A051902, A randomized phase II study of CHO(E)P vs CC-486- CHO(E)P vs duvelisib- CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas

An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma